Last checked at 30 Jun 2010 16:27
Proteome Sciences plc
("Proteome Sciences" or "the Company")
RESULT OF AGM, LOAN CONVERSION AND TOTAL VOTING RIGHTS
Cobham, UK, 30 June 2010 - Proteome Sciences is pleased to announce that, at the Company's Annual General Meeting (the "AGM") held earlier today all resolutions were duly passed.
The Company is also pleased to announce that following approval by shareholders at the Company's AGM, the conversion has now taken place of £5 million of the loan provided to the Company by Christopher Pearce, Chief Executive, into 25,000,000 ordinary shares of 1 pence each ("Ordinary Shares") (the "Loan Conversion"). The Loan Conversion was done at 20 pence per share, representing the placing price of the firm placing (the "Firm Placing") and open offer (the "Open Offer") which together raised £6.9 million before expenses. The Firm placing and Open Offer completed on 18 June and 28 June respectively.
Following the Loan Conversion, Christopher Pearce is interested in 31,538,075 Ordinary Shares representing 16.41 per cent. of the Company's issued share capital.
Application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 25,000,000 new Ordinary Shares. It is expected that Admission will become effective on 1 July 2010. The new Ordinary Shares, when issued and fully paid will rank equally in all respects with the Existing Ordinary Shares, including the right to receive all dividends or other distributions made, paid or declared.
Following the Firm Placing, Open Offer and Loan Conversion the Company's issued share capital will consist of 192,172,408 Ordinary Shares, with voting rights (one vote per ordinary share). The Company does not hold any ordinary shares in Treasury.
Therefore, the total number of Ordinary Shares in the Company with voting rights is 192,172,408.
The above figure of 192,172,408 ordinary shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FSA's Disclosure and Transparency Rules.
-Ends-
For further information please contact:
Proteome Sciences plc
www.proteomics.com Tel: +44 (0)1932 865065
Christopher Pearce, Chief Executive christopher.pearce@proteomics.com
James Malthouse, Finance Director james.malthouse@proteomics.com
Dr. Ian Pike, Chief Operating Officer ian.pike@proteomics.com
Nominated Adviser
Singer Capital Markets Limited
Shaun Dobson/Claes Spång
Tel: +44 (0)20 3205 7500
Public Relations
IKON Associates Redleaf Communications Limited
Adrian Shaw Anna Dunkin/Lucy Salaman
Tel: +44 (0)1483 535102 Tel: +44 (0)20 7566 6700
Mobile: +44 (0)7979 900733 Email: proteome@redleafpr.com
Email: adrian@ikonassociates.com
Forward Looking Statement
This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections.
Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements and regional, national, global political, economic, business, competitive, market and regulatory conditions.